TRIM11 and Parkinson disease: TRIM11 dissolves α-synuclein fibrils in vitro, converting them into soluble forms in a dose-dependent manner and suppressing α-synuclein toxicity, as seen in cell and mouse models of Parkinson’s disease (PD).